|   In the News

A Talk With Robert Jacks, New CEO of NASH and Fibrotic Drugmaker Indalo

Robert Jacks, co-founder and former chief financial officer of Symbiomix Therapeutics, has taken over the reins of Cambridge, Mass.-based Indalo Therapeutics and will help guide the company in the development of therapies for patients suffering from serious fibrotic diseases such as NASH and idiopathic pulmonary fibrosis (IPF).

Read more.


  |   From the Trenches

Predicting The Next Dominoes to Fall in 2019

Today I will continue my time-honored January tradition of an optimistic blog post providing some bold predictions for the year ahead.

This post was written by Michael Gladstone, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   From the Trenches

Leadership At All Levels In Biotech

Biotech is an industry that calls for leaders. It requires people who are willing to take risks, conquer new science, and have endurance for the many years it takes to develop a new medicine. In addition, professionals who thrive in biotech have the know-how, confidence and guts to tackle business goals that are covered in uncertainty and complexity. These are ‘hard core’ leadership traits, and they are highly valued in biotech companies at all levels of job responsibilities.

This blog was written by Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC

Read more.


  |   LifeSciVC

Venture Volatility: 2018’s Banner Year Closed Cautiously

By Bruce Booth, DPhil, Partner

2018 was a gangbuster year for VC-funding into startups, reaching levels not seen since the height of the dot-com and genomics era.

Read more.


  |   LifeSciVC

The Game Isn’t Worth The Candle: Reflections On The JPM Healthcare Conference

By Bruce Booth, DPhil, Partner

Another year, another JPM week. With a weekend to recuperate and reflect, I come away more concerned than ever about JPM and our industry.

Read more.